Global Orthostatic Hypotension Drugs Market, By Diagnostic Test Type (ECG, Blood Tests, Stress Test, Other), Drug Type (Fludrocortisone, Midodrine Hydrochloride, Droxidopa, Pyridostigmine, Indomethacin, Caffeine, Epoetin, Oxilofrine Potassium Chloride, NSAIDs (Nonsteroidal anti-Inflammatory Drugs)), End user (Hospitals, ASCs and Clinics, Others) – Industry Trends and Forecast to 2030.
Orthostatic Hypotension Drugs Market Analysis and Size
Orthostatic hypotension is widespread in people 65 and older. Physicians should keep a high index of suspicion when giving medications that are frequently known to induce this illness, especially in the elderly, because orthostatic hypotension is easily detectable by methods that are accessible to all doctors. The screening and monitoring of orthostatic hypotension should be implemented as a regular precaution in suitable patients due to the prevalent medical disorders requiring these medications. 2/3 of older individuals have hypertension. Orthostatic hypotension is a rare side effect of most medications used to treat hypertension; nevertheless, it is more frequent with alpha 1-blockers (initial dosage), adrenergic blockers, and medications with central actions.
Data Bridge Market Research analyses that the orthostatic hypotension drugs market, which was USD 744.93 million in 2022, is expected to reach USD 1,313.81 million by 2030, at a CAGR of 7.35% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Orthostatic Hypotension Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diagnostic Test Type (ECG, Blood Tests, Stress Test, Other), Drug Type (Fludrocortisone, Midodrine Hydrochloride, Droxidopa, Pyridostigmine, Indomethacin, Caffeine, Epoetin, Oxilofrine Potassium Chloride, NSAIDs (Nonsteroidal anti-Inflammatory Drugs)), End user (Hospitals, ASCs and Clinics, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Mylan N.V. (U.S.), Upsher-Smith Laboratories, LLC (U.S.), Chelsea Therapeutics International, Ltd (U.S.), Amgen Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Apotex Inc (Canada), Pfizer Inc. (U.S.), Novartis AG (Germany), H. Lundbeck A/S (Denmark) and Amneal Pharmaceuticals LLC (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Orthostatic hypotension, also known as postural hypotension, is a condition characterized by dizziness caused by low blood pressure. It is common when a person stands up from a long sitting and experiences dizziness. Dehydration, heart, endocrine, and nervous system disorders can all contribute to it. It has also been discovered that elderly nursing home residents are more susceptible to O.H. than those living in the community. When a person has orthostatic hypotension, their diastolic blood pressure drops by at least 10 mm Hg, and their systolic blood pressure drops by at least 20 mm Hg.
Global Orthostatic Hypotension Drugs Market Dynamics
Drivers
- Increasing prevalence of chronic diseases
The risk of O.H. is rising due to the global rise in diabetes, cardiovascular illness, and neurodegenerative diseases. It is linked to a dysfunction of the autonomic nervous system. Dehydration is another prevalent illness that raises the risk of O.H. and harms the nerves in humans. The global market for drugs to treat orthostatic hypotension is expected to grow at a CAGR of nearly 8% during the forecast period due to the rise in the prevalence of chronic diseases linked to a high risk of O.H.
- The rise in the use of combination therapy in O.H. treatment
O.H. is a persistent, disabling condition that can be challenging to manage in certain patients. Orthostatic stress varies throughout the day; therefore, treating O.H. patients with a single medication may not be sufficient. As a result, the use of combination therapy in the treatment of O.H. is receiving more attention. This development is anticipated to boost market expansion.
Opportunities
- Increasing demand for diagnosis tests
A stress test is performed during exercise, such as treadmill walking. People who cannot exercise may be given medication to force their hearts to work harder. Electrocardiography, echocardiography, or other tests are then used to monitor the heart. Thus, these tests are commonly used to diagnose the patient's condition for the fastest recovery, and thus, it creates many opportunities for the drug development processes.
Restraints/Challenges
- The lack of clinical evidence
The adoption of non-pharmacological treatment options such as first-line therapy, low diagnosis rates, a lack of clinical evidence, and unfavorable safety profiles of O.H. drugs, among other factors, could impede the growth of the orthostatic hypotension drugs market during the forecast period. The drugs that can increase the risk of orthostatic hypotension include narcotics, some antidepressants, some antipsychotics, muscle relaxants, and drugs used to treat erectile dysfunction and Parkinson's disease.
This orthostatic hypotension drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the orthostatic hypotension drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Orthostatic Hypotension Drugs Market Scope
The orthostatic hypotension drugs market is segmented on the basis of diagnosis test type, drug type and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnostic Test Type
- ECG
- Blood Test
- Stress Test
- Other
Drug Type
- Fludrocortisone
- Midodrine Hydrochloride
- Droxidopa
- Pyridostigmine
- Indomethacin
- Caffeine
- Epoetin
- Oxilofrine Potassium Chloride
- NSAIDs (Nonsteroidal anti-Inflammatory Drugs)
End user
- Hospitals
- ASCs
- Clinics
- Others
Orthostatic Hypotension Drugs Market Regional Analysis/Insights
The orthostatic hypotension drugs market is analysed and market size insights and trends are provided by country, diagnosis test type, drug type and end-user as referenced above.
The countries covered in the orthostatic hypotension drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the orthostatic hypotension drugs market due to the adoption of technologically advanced tools to improve healthcare infrastructure to reduce patient waiting time and maximize bed utilization in this region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030, owing to the growing awareness of drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Orthostatic Hypotension Drugs Market Share Analysis
The orthostatic hypotension drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to orthostatic hypotension drugs market.
Some of the major players operating in the orthostatic hypotension drugs market are:
- Mylan N.V. (U.S.)
- Upsher-Smith Laboratories, LLC (U.S.)
- Chelsea Therapeutics International, Ltd (U.S.)
- Amgen Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Apotex Inc (Canada)
- Pfizer Inc. (U.S.)
- Novartis AG (Germany)
- H. Lundbeck A/S (Denmark)
- Amneal Pharmaceuticals LLC (U.S.)
SKU-